Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 65343E207 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Squadron Capital Management LLC
13G/A
Amendment 2
|
1.6% |
8/14/2026
Event 6/30/2026
|
|
| Squadron Master Fund LP | 1.6% | ||
| Squadron Capital Management LLC | 1.6% | ||
| Matthew Sesterhenn | 1.6% | ||
| William Blank | 1.6% | ||
|
Ikarian Capital, LLC
13G/A
Amendment 1
|
10.0% |
8/14/2026
Event 6/30/2026
|
|
| Ikarian Capital, LLC | 10.0% | ||
| Neil Shahrestani | 10.0% | ||
|
ADAR1 Capital Management, LLC
13G
|
15.8% |
8/14/2026
Event 7/31/2026
|
|
| ADAR1 Capital Management, LLC | 15.8% | ||
| Daniel Schneeberger | 15.8% | ||
|
Affinity Asset Advisors, LLC
13G/A
Amendment 4
|
6.4% |
8/13/2026
Event 6/30/2026
|
|
| Affinity Asset Advisors, LLC | 6.4% | ||
| Michael Cho | 6.4% | ||
|
Adage Capital Management, L.P.
13G
|
7.7% |
8/12/2026
Event 6/30/2026
|
|
| Adage Capital Management, L.P. | 7.7% | ||
| Robert Atchinson | 7.7% | ||
| Phillip Gross | 7.7% | ||
|
SilverArc Capital Management, LLC
13G/A
Amendment 1
|
4.9% |
5/13/2026
Event 3/31/2026
|
|
| SilverArc Capital Management, LLC | 4.9% | ||
| Devesh Gandhi | 4.9% | ||
|
Simcere Zaiming, Inc.
13G/A
Amendment 1
|
9.4% |
5/6/2026
Event 12/31/2025
|
|
| Simcere Zaiming, Inc. | 9.4% | ||
| Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. | 9.4% | ||
| Simcere Zaiming Pharmaceutical Co., Ltd. | 9.4% | ||
| Simcere Pharmaceutical Group Limited | 9.4% | ||
| Ren Jinsheng | 9.4% | ||
| Tang Renhong | 9.4% | ||
|
Sofinnova Venture Partners IX, L.P.
13D/A
Amendment 2
|
7.1% |
3/5/2026
Event 12/19/2025
|
|
| Sofinnova Venture Partners IX, L.P. ("SVP IX") | 7.1% | ||
| Sofinnova Management IX, L.L.C. ("SM IX") | 7.1% | ||
| Dr. James I. Healy ("Healy") | 7.1% | ||
|
Squadron Capital Management LLC
13G/A
Amendment 1
|
9.9% |
2/17/2026
Event 12/31/2025
|
|
| Squadron Master Fund LP | 9.9% | ||
| Squadron Capital Management LLC | 9.9% | ||
| Matthew Sesterhenn | 9.9% | ||
| William Blank | 9.9% | ||
|
Ikarian Capital, LLC
13G
|
10.0% |
2/17/2026
Event 12/31/2025
|
|
| Ikarian Capital, LLC | 10.0% | ||
| Neil Shahrestani | 10.0% | ||
|
SilverArc Capital Management, LLC
13G
|
5.0% |
2/12/2026
Event 12/31/2025
|
|
| SilverArc Capital Management, LLC | 5.0% | ||
| Devesh Gandhi | 5.0% | ||
|
Affinity Asset Advisors, LLC
13G/A
Amendment 3
|
10.0% |
1/29/2026
Event 1/22/2026
|
|
| Affinity Asset Advisors, LLC | 10.0% | ||
| Michael Cho | 10.0% | ||
|
Affinity Asset Advisors, LLC
13G/A
Amendment 2
|
7.2% |
11/14/2025
Event 9/30/2025
|
|
| Affinity Healthcare Fund, LP | 7.2% | ||
| Affinity Asset Advisors, LLC | 7.2% | ||
|
Squadron Capital Management LLC
13G
|
6.5% |
10/24/2025
Event 10/21/2025
|
|
| Squadron Master Fund LP | 5.8% | ||
| Squadron Capital Management LLC | 6.5% | ||
| Matthew Sesterhenn | 6.5% | ||
| William Blank | 6.5% | ||
|
Simcere Zaiming, Inc.
13G
|
12.7% |
8/19/2025
Event 6/20/2025
|
|
| Simcere Zaiming, Inc. | 12.7% | ||
| Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. | 12.7% | ||
| Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | 12.7% | ||
| Simcere Pharmaceutical Group Limited | 12.7% | ||
| Ren Jinsheng | 12.7% | ||
| Tang Renhong | 12.7% |